# Protagonist Therapeutics

Type: Company (PTGX)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/protagonist-therapeutics
Canonical HTML page: https://gethealthbrief.com/entity/protagonist-therapeutics

## Timeline

- **2026-Q4**: Data Readout — Anticipated top-line data from the Phase 3 VERIFY clinical trial.
- **2026-03-18**: Q4 Earnings — Scheduled announcement of quarterly financial results and pipeline update.
- **2025-01-10**: VERIFY Enrollment — Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
- **2024-05-15**: J&J Milestone — Protagonist receives $231M milestone payment for icotrokinra progress.

## Recent coverage (2 stories)

### How Protagonist’s $620M Cash Runway Through 2028 Supports 2 Peptide Drug Launches
2026-06-14 01:25:03 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-620m-cash-runway-2-drug-launches-health

### Protagonist Therapeutics Eyes Pivotal Q4 Results Amid Oral Peptide Expansion
2026-03-17 07:33:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-q4-earnings-preview-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.